Alzheimer Diagnostic Testing Devices Pipeline Assessment, 2020 Report Featuring Over 130 Companies - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Alzheimer Diagnostic Tests - Medical Devices Pipeline Assessment, 2020" report has been added to ResearchAndMarkets.com's offering.

"Alzheimer Diagnostic Tests - Medical Devices Pipeline Assessment, 2020". Alzheimer Diagnostic Tests are tests that detect the disease before it causes symptoms. It measures key proteins or protein patterns in blood or spinal fluid (biomarkers).

Scope

• Extensive coverage of the Alzheimer Diagnostic Tests under development
• The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
• The report reviews the major players involved in the development of Alzheimer Diagnostic Tests and list all their pipeline projects
• The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
• The report provides key clinical trial data of ongoing trials specific to pipeline products
• Recent developments in the segment / industry

Reasons to Buy

The report enables you to -

• Formulate significant competitor information, analysis, and insights to improve R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand important and diverse types of Alzheimer Diagnostic Tests under development
• Develop market-entry and market expansion strategies
• Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
• In-depth analysis of the product's current stage of development, territory and estimated launch date

Key Topics Covered:

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Alzheimer Overview

3 Products under Development

3.1 Alzheimer - Pipeline Products by Stage of Development

3.2 Alzheimer - Pipeline Products by Territory

3.3 Alzheimer - Pipeline Products by Regulatory Path

3.4 Alzheimer - Pipeline Products by Estimated Approval Date

3.5 Alzheimer - Ongoing Clinical Trials

4 Alzheimer - Pipeline Products under Development by Companies

4.1 Alzheimer Companies - Pipeline Products by Stage of Development

4.2 Alzheimer - Pipeline Products by Stage of Development

5 Alzheimer Companies and Product Overview

6 Alzheimer- Recent Developments

7. Appendix

Companies Mentioned

• AC Immune SA
• Acobiom
• Acumen Pharmaceuticals Inc
• Adlyfe Inc
• Admit Therapeutics SL
• ADx NeuroSciences NV
• Aelan Cell Technologies
• Agent Biotech
• Albert Ludwigs University of Freiburg
• Alere Inc
• Alzhyme Pty Ltd
• Alzinova AB
• Amarantus Bioscience Holdings Inc
• Amarantus Diagnostics Inc
• Ambergen Inc
• Amco International Manufacturing Inc.
• Amoneta Diagnostics SAS
• Amprion Inc
• Applied NeuroSolutions, Inc. (Inactive)
• Arkley Biotek LLC
• attyloid GmbH
• Banyan Biomarkers Inc
• BioArctic AB
• Bioasis Technologies Inc
• Biocross SL
• Biomedical Development Corp
• BioSystems International
• Boston University Medical Campus
• Brigham and Women's Hospital
• C2N Diagnostics LLC
• Calviri Inc
• Cassava Sciences Inc
• Chronix Biomedical Inc
• Cleveland Diagnostics Inc.
• Cofactor Genomics Inc
• Cognext Diagnostics LLC
• Columbia University
• CompanDX Ltd
• Cymedx
• Cytox Ltd
• Diadem SRL
• DiamiR LLC
• DiaPat GmbH
• Durin Technologies, Inc.
• Emory University
• Eurobio Scientific SA
• Florida Institute of Technology
• French National Institute of Health and Medical Research
• Fujirebio Diagnostics Inc
• Fujirebio Europe NV
• GenoScreen SAS
• Ghent University
• IBM Research-Australia
• ICDD-sas
• Inbiomed
• Innosense LLC
• Innovative Health Diagnostics
• Instituto de Estructura de la Materia
• Integrated Diagnostics Inc (Inactive)
• Janssen Pharmaceutica NV
• Johns Hopkins University
• Johns Hopkins University School of Medicine
• KineMed Inc
• King's College London
• Lund University
• McGill University Health Center
• Medifron DBT Inc
• Memory Dx LLC
• Meso Scale Diagnostics LLC
• Michigan State University
• Myriad RBM Inc
• NanoSomiX, Inc.
• Nanosphere Inc
• National University of Singapore
• Nel ASA
• NeoNeuro SAS
• Neuro Bio Ltd
• NeuroDiagnostics LLC
• NeuroQuest Ltd
• Neurotrope Bioscience Inc
• Newcastle University
• Novel Bio-spectrum Technologies Inc (Inactive)
• Oligomerix inc
• Orasi Medical, Inc. (Inactive)
• Oryzon Genomics SA
• Peri Rx Inc
• Pre Diagnostics AS
• Predemtec GmbH
• ProMIS Neurosciences Inc
• Proplex Technologies Llc
• Protagen AG
• Proteome Sciences Plc
• Proteomics International Laboratories Ltd
• Quanterix Corp
• Redox Diagnostics LLC
• Roche Diagnostics GmbH
• Roche Diagnostics International Ltd
• Ruhr-University Bochum
• Scout Diagnostics LLC
• Seer Biosciences Inc
• Siemens Healthineers AG
• StageZero Life Sciences Ltd
• TauRx Pharmaceuticals Ltd
• The Florey Institute of Neuroscience and Mental Health
• The University of Nottingham
• TopoGEN Inc
• Trinity College Dublin
• True Diagnostics Inc
• University of Calgary
• University of California San Diego
• University of California San Francisco
• University of Chicago
• University of Georgia
• University of Gottingen
• University of Illinois at Chicago
• University of Luxembourg
• University of Maryland Baltimore
• University of Melbourne
• University of Oxford
• University of Pittsburgh
• University of South Florida
• University of Texas Health Science Center at Houston
• University of Texas Southwestern Medical Center
• Urvogelbio Pvt Ltd
• US Biomarkers Inc
• vall d hebron institut de Recerca
• Veravas Inc
• Vitruvian Biomedical Inc
• Washington University in St Louis
• Washington University School of Medicine
• Zoiray Technologies Inc.

For more information about this report visit https://www.researchandmarkets.com/r/fyvop6